CA2487171A1 - Procede pour proteger les cellules endotheliales et epitheliales au cours d'une chimiotherapie - Google Patents

Procede pour proteger les cellules endotheliales et epitheliales au cours d'une chimiotherapie Download PDF

Info

Publication number
CA2487171A1
CA2487171A1 CA002487171A CA2487171A CA2487171A1 CA 2487171 A1 CA2487171 A1 CA 2487171A1 CA 002487171 A CA002487171 A CA 002487171A CA 2487171 A CA2487171 A CA 2487171A CA 2487171 A1 CA2487171 A1 CA 2487171A1
Authority
CA
Canada
Prior art keywords
cells
defibrotide
immunosuppressant
use according
protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002487171A
Other languages
English (en)
Inventor
Guenther Eissner
Ernst Holler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitätsklinikum Regensburg
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2487171A1 publication Critical patent/CA2487171A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne l'utilisation d'un oligodésoxyribonucléotide protecteur pour traiter un patient en cours de traitement par immunosuppresseur. L'invention a également pour objet une composition pharmaceutique contenant une dose efficace du point de vue thérapeutique d'un immunosuppresseur et d'un oligodésoxyribonucléotide protecteur.
CA002487171A 2002-05-31 2003-06-02 Procede pour proteger les cellules endotheliales et epitheliales au cours d'une chimiotherapie Abandoned CA2487171A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38411402P 2002-05-31 2002-05-31
US60/384,114 2002-05-31
US38743802P 2002-06-11 2002-06-11
US60/387,438 2002-06-11
PCT/EP2003/005753 WO2003101468A1 (fr) 2002-05-31 2003-06-02 Procede pour proteger les cellules endotheliales et epitheliales au cours d'une chimiotherapie

Publications (1)

Publication Number Publication Date
CA2487171A1 true CA2487171A1 (fr) 2003-12-11

Family

ID=29715309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002487171A Abandoned CA2487171A1 (fr) 2002-05-31 2003-06-02 Procede pour proteger les cellules endotheliales et epitheliales au cours d'une chimiotherapie

Country Status (16)

Country Link
EP (1) EP1509235A1 (fr)
JP (1) JP2005527636A (fr)
CN (1) CN1304011C (fr)
AU (1) AU2003238189A1 (fr)
CA (1) CA2487171A1 (fr)
EA (1) EA008213B1 (fr)
HR (1) HRP20041213A2 (fr)
IL (1) IL165353A0 (fr)
IS (1) IS7548A (fr)
MX (1) MXPA04011941A (fr)
NO (1) NO20045655L (fr)
NZ (1) NZ536864A (fr)
PL (1) PL374402A1 (fr)
RS (1) RS102504A (fr)
UA (1) UA83628C2 (fr)
WO (1) WO2003101468A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP2637672B1 (fr) * 2010-11-12 2018-08-22 Gentium S.r.l. Défibrotide pour une utilisation dans la prophylaxie et/ou le traitement de la maladie du greffon contre l'hôte (mgch)
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
EP3026122A1 (fr) 2014-11-27 2016-06-01 Gentium S.p.A. Procédé à base cellulaire pour déterminer la puissance de défibrotide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof

Also Published As

Publication number Publication date
MXPA04011941A (es) 2005-07-26
CN1655801A (zh) 2005-08-17
NO20045655L (no) 2004-12-27
PL374402A1 (en) 2005-10-17
NZ536864A (en) 2008-08-29
WO2003101468A1 (fr) 2003-12-11
JP2005527636A (ja) 2005-09-15
EA200401448A1 (ru) 2005-06-30
IL165353A0 (en) 2006-01-15
AU2003238189A1 (en) 2003-12-19
IS7548A (is) 2004-11-24
HRP20041213A2 (hr) 2006-04-30
EP1509235A1 (fr) 2005-03-02
UA83628C2 (ru) 2008-08-11
CN1304011C (zh) 2007-03-14
RS102504A (sr) 2006-12-15
EA008213B1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
Mulder et al. Therapeutic targeting of trained immunity
US20200147117A1 (en) Combination cancer therapy
Eissner et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide
JP2004510691A (ja) カルボキサミジンで修飾した二環式塩基を有するヌクレオシドアナログ
PT1385498E (pt) Ácidos gordos como factores de sobrevivência e activação de neutrófilos
PL199852B1 (pl) Zastosowanie skutecznej ilości agonisty receptora adenozynowego A3
KR20250048489A (ko) 줄기 세포 이식을 위한 방법
WO2017046108A1 (fr) Compositions de dactinomycine et méthodes de traitement de la leucémie aiguë myéloïde
US20210169912A1 (en) Cladribine regimen for treating progressive forms of Multiple Sclerosis
EP4252754A1 (fr) Composition pharmaceutique pour améliorer l'élimination de cellules et son utilisation
EP0994702B1 (fr) Composition contenant un nucleotide
US20080254037A1 (en) Method of treating ischemia reperfusion injury by inhibing nkt cell activity
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
US20050215498A1 (en) Method for the protection of endothelial and epithclial cells during chemotherapy
CA2487171A1 (fr) Procede pour proteger les cellules endotheliales et epitheliales au cours d'une chimiotherapie
US20030143282A1 (en) Adenosine A3 receptor agonist
ZA200409558B (en) Method for the protection of endothelial and epithelial cells during chemotherapy.
Park et al. A multicenter, randomized, open-label study to compare the efficacy and safety of tacrolimus and corticosteroids in combination with or without mycophenolate mofetil in liver transplantation recipients infected with hepatitis B virus
EP4665386A1 (fr) Compositions, systèmes et méthodes de traitement du cancer à l'aide de champs de traitement de tumeurs et de cellules tueuses
JP7535285B2 (ja) 腫瘍関連マクロファージ賦活化剤
KR20050024299A (ko) 화학 요법 중의 내피 및 상피 세포의 보호 방법
JP7217875B2 (ja) 血液がんの予防及び／又は治療剤
JPH10505323A (ja) ２−ハロ−２’−デオキシアデノシンによる炎症性腸疾患の治療
KR20090009963A (ko) 면역학적 질병의 치료를 위한 티모신 알파 1의 용도
AU2005304320A1 (en) Methods of treating hematological malignancies with nucleoside analog drugs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued